TOPLINE:
Beta-blocker use is associated with a 34% reduction of onset in premanifest Huntington disease (preHD) and slower progression in early motor-manifest Huntington disease (mmHD), new research shows.
METHODOLOGY:
- In this longitudinal multicenter study, 174 beta-blocker users with preHD (mean age, 46.4 years; 66% women) were matched with 174 nonusers (mean age, 48 years; 66% women).
- Researchers also assessed 149 beta-blocker users with mmHD (mean age, 59 years; 58% men) who were matched with 149 nonusers (mean age, 59 years; 61% men).
- Data were obtained from the Enroll-HD platform database (initiated in September 2011) for participants with uninterrupted beta-blocker use for more than 1 year.
- Primary outcomes included risk for motor diagnosis for preHD and progression rates of total motor score, total functional…